Vanda Pharmaceuticals Inc
NASDAQ:VNDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vanda Pharmaceuticals Inc
NASDAQ:VNDA
|
US |
|
Solomon Systech (International) Ltd
HKEX:2878
|
HK |
|
Genius Electronic Optical Co Ltd
TWSE:3406
|
TW |
|
Tway Holdings Inc
KRX:004870
|
KR |
|
Q
|
QuantaSing Group Ltd
NASDAQ:QSG
|
CN |
|
Astronics Corp
NASDAQ:ATRO
|
US |
|
Nihon Parkerizing Co Ltd
TSE:4095
|
JP |
|
A
|
Avantel Ltd
BSE:532406
|
IN |
|
Gold Peak Technology Group Ltd
HKEX:40
|
HK |
|
Sembcorp Marine Ltd
SGX:S51
|
SG |
|
Precipio Inc
NASDAQ:PRPO
|
US |
|
Iervolino & Lady Bacardi Entertainment SpA
MIL:IE
|
IT |
|
T
|
TransGlobe Energy Corp
LSE:TGL
|
CA |
|
North Electro-Optic Co Ltd
SSE:600184
|
CN |
|
N
|
Nurminen Logistics Oyj
OMXH:NLG1V
|
FI |
|
Zheneng Jinjiang Environment Holding Co Ltd
SGX:BWM
|
CN |
|
ASA International Group PLC
LSE:ASAI
|
NL |
|
K
|
Kayne Anderson BDC Inc
NYSE:KBDC
|
US |
|
Paccar Inc
NASDAQ:PCAR
|
US |
|
Atlas Copco AB
STO:ATCO A
|
SE |
|
G
|
Garg Furnace Ltd
BSE:530615
|
IN |
|
Whitecap Resources Inc
TSX:WCP
|
CA |
|
F
|
Future PLC
F:FNWA
|
UK |
Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 278 full-time employees. The company went IPO on 2006-04-12. The company is focused on the development and commercialization of therapies to address unmet medical needs. Its commercial portfolio consists of two products, such as HETLIOZ (tasimelteon) and Fanapt (iloperidone). Tasimelteon is used for the treatment of jet lag disorder, delayed sleep phase disorder (DSPD), symptoms of autism spectrum disorder (ASD) and pediatric Non-24-Hour Sleep-Wake Disorder (Non-24). Iloperidone is used for the treatment of bipolar disorder and Parkinson's disease psychosis and is a long acting injectable (LAI) formulation for the treatment of schizophrenia. Its other product pipeline includes Tradipitant (VLY-686), VTR-297, VSJ-110 and BPO-27. VLY-686, is for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. VTR-297, is for the treatment of hematologic malignancies and use as a treatment for oncology indications. Its other products include VQW-765 and VHX-896.
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 278 full-time employees. The company went IPO on 2006-04-12. The company is focused on the development and commercialization of therapies to address unmet medical needs. Its commercial portfolio consists of two products, such as HETLIOZ (tasimelteon) and Fanapt (iloperidone). Tasimelteon is used for the treatment of jet lag disorder, delayed sleep phase disorder (DSPD), symptoms of autism spectrum disorder (ASD) and pediatric Non-24-Hour Sleep-Wake Disorder (Non-24). Iloperidone is used for the treatment of bipolar disorder and Parkinson's disease psychosis and is a long acting injectable (LAI) formulation for the treatment of schizophrenia. Its other product pipeline includes Tradipitant (VLY-686), VTR-297, VSJ-110 and BPO-27. VLY-686, is for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. VTR-297, is for the treatment of hematologic malignancies and use as a treatment for oncology indications. Its other products include VQW-765 and VHX-896.
Revenue Growth: Total revenues for 2025 reached $216.1 million, up 9% year-over-year, driven mainly by strong Fanapt performance.
Fanapt Surge: Fanapt net product sales rose 24% to $117.3 million for 2025, with total prescriptions up 28% and new-to-brand prescriptions up 149%.
2026 Guidance: Management expects 2026 revenues from existing commercial products to be $230–$260 million, with Fanapt sales targeted at $150–$170 million.
Pipeline Progress: FDA approved Nereus (tradipitant) for motion sickness in late 2025, with launches and label expansions planned; multiple late-stage clinical programs are advancing.
HETLIOZ Decline: HETLIOZ sales fell 7% year-over-year to $71.4 million amid continuing generic competition.
Net Loss Impact: 2025 net loss widened to $220.5 million due to a large noncash tax charge and higher operating expenses.
Commercial Investments: Significant expansion of sales force and increased direct-to-consumer campaigns supported prescription growth, especially for Fanapt.
